Psychiatrist - Bryker Woods (Greenbrook)

Greenbrook
United States, Texas, Austin
Jul 20, 2026
Greenbrook Mental Wellness Centers, a subsidiary of Neuronetics, Inc., is seeking a Board Certified or Board Eligible Psychiatrist to provide onsite oversight of Transcranial Magnetic Stimulation (TMS) treatments and support the growth of our Spravato (esketamine) program in Austin, TX. Why Join Us? Flexible schedule No nights, weekends, or on-call responsibilities Competitive compensation TMS certification and training provided Opportunity to expand your expertise in interventional psychiatry Collaborative clinical and operational support team Make a meaningful impact on patients with treatment-resistant depression and other mental health disorders Qualifications MD or DO Board Certified or Board Eligible Active Texas medical license (or ability to obtain) DEA registration (or ability to obtain) About Greenbrook Greenbrook Mental Wellness Centers, a subsidiary of Neuronetics, Inc., is a leading provider of TMS and Spravato therapies, delivering innovative, evidence-based treatments for depression, OCD, and other mental health conditions. Through a nationwide network of treatment centers, Greenbrook is helping patients find relief when traditional treatments have not been successful. Join us in transforming mental health care and improving lives. Learn More Provider Information: Greenbrook for Providers \| TMS Therapy & Esketamine Patient Stories: Patient Stories \| Greenbrook Our Why: https://youtu.be/yrr-wlFftT0 GBSP25 About Us Neuronetics, Inc. is a leading mental healthcare company, now encompassing Greenbrook TMS as a subsidiary. This strategic acquisition unites Neuronetics' innovative NeuroStar Advanced Therapy (TMS) technology with Greenbrook's extensive network of over 95 U.S. treatment centers. The combined company provides FDA-cleared NeuroStar TMS and Spravato treatments for major depressive disorder (MDD) and treatment-resistant depression. With a strengthened nationwide footprint, Neuronetics is dedicated to significantly expanding patient access to these crucial therapies, integrating advanced technology with established clinical expertise to improve patient outcomes and drive growth within the mental health sector.